Etid klinik pou Obèsite nan Alabama
40 etid pou Obèsite ap chèche patisipan nan sit nan Alabama.
Vil nan Alabama
Tèks ofisyèl etid la (Anglè)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Heart Center Research, LLC, Huntsville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07783802AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- Univ of Alabama Birmingham, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07533175Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- AMR Clinical - Mobile, Mobile
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07685808A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
- Cullman Clinical Trials, Cullman
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07823608Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Cahaba Research - Pelham /ID# 282381, Pelham
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07752979AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Pinnacle Research Group LLC, Anniston
- Univ of Alabama Birmingham, Birmingham
- Chambliss Clinical Trials LLC, Montgomery
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07720271Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- University of Alabama - Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07837973Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Digestive Health Specialists, Dothan
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Digestive Health Specialists, Dothan
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Birmingham Clinical Research, Birmingham
- Cullman Clinical Trials, Cullman
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Alliance For Multispecialty Research - Daphne, Daphne
- Eastern Shore Research Institute, Fairhope
- Heart Center Research LLC, Huntsville
- ak 2 plis
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- AMR Clinical, Mobile
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- MFA Clinical Research, Tuscaloosa
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fairhope
- Research Site, Huntsville
- Research Site, Mobile
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Birmingham Clinical Research, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Cullman Clinical Trials, Cullman
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07369011Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- University of Alabama Saint Vincent's Birmingham, Birmingham
- SEC Clinical Research, Dothan
- Eastern Shore Research Institute, Fairhope
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT07037459A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Birmingham
- AURORA-2 Clinical Site, Huntsville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Birmingham
- AURORA-1 Clinical Site, Huntsville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lakeview Clinical Research, Guntersville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Pinnacle Research Group, Anniston
- Alabama Clinical Therapeutics, Birmingham
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Birmingham
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Uni of Alabama at Birmingham, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07770841Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Cullman
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Anniston
- Kailera Clinical Site, Birmingham
- Kailera Clinical Site, Cullman
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Pinnacle Research Group LLC, Anniston
- Alliance For Multispecialty Research - Daphne, Daphne
- Alliance for Multispecialty Research Mobile, Mobile
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Cahaba Research, Inc., Pelham
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Dothan
- Research Site, Huntsville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Advanced Cardiovascular, LLC, Alexander City
- Univ of Alabama Birmingham, Birmingham
- Eastern Shore Rsrch Inst, LLC, Fairhope
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Birmingham
- ACCOMPLISH-1 Research Site, Birmingham
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Pinnacle Research Group, Anniston
- Cullman Clinical Trials, Cullman
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Jul 22, 2026 · NCT07477704Time-restricted Eating for Postpartum Weight Loss
- University of Alabama at Birmingham, Birmingham
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Jun 29, 2026 · NCT06491537Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Alabama at Birmingham, Birmingham
Ap rekrite
Laj 18 a 45 · Fanm · Mizajou Jun 24, 2026 · NCT05124808PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2/3Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT04971720GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
- University of Alabama at Birmingham, Birmingham
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT05216042Ketogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity
- University of Alabama at Birmingham, Birmingham
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Apr 7, 2026 · NCT06736028CARBON: UAB Cardiovascular Research Biobank
- University of Alabama at Birmingham, Birmingham
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05067231FELLAShip to Better Health
- The Worship Center Cristian Church, Birmingham
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Jan 22, 2026 · NCT07220213Inspire HER: Inspiring the Heart and Emotions for Radical Health
- University of Alabama at Birmingham, Birmingham
Ap rekrite
Laj 30 a 79 · Fanm · Mizajou Dec 29, 2025 · NCT06966258A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
- UAB Pediatric Endocrinology (Part C and Part D), Birmingham
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 65 · Tout sèks · Mizajou Dec 22, 2025 · NCT06239116Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.